Fig. 7
Effect of the PI3K inhibitor wortmannin on regulatory B cells (Bregs), tumor-infiltrating immune cells, and peritoneal tumor growth. (A) Comparison of ascites volume and peritoneal tumor weight between the control and wortmannin-treated model (**p < 0.01, ***p < 0.001). Each group consisted of 6 mice. (B) Flow cytometry analysis of Bregs from the spleen, ascites, and peritoneal tumors in the control and wortmannin-treated model (*p < 0.05, **p < 0.01). (C) Infiltration of CD8+ T cells and M2 macrophages in the spleen, ascites, and peritoneal tumors in control and wortmannin-treated models (*p < 0.05, **p < 0.01, ***p < 0.001). The results are provided in terms of means ± standard deviation values.
